Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia

 Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia

Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia

Shots:

  • Udenyca’s (Pegfilgrastim biosimilar) EU approval is based on the data demonstrating its PK and PD, for reducing the chances of infection by febrile neutropenia
  • This biosimilar is currently under the US FDA inspection and has provided a PDUFA date 3 Nov, 2018. Udenyca is currently not available for commercial sale
  • Udenyca (pegfilgrastim-cbqv/CHS-1701), is a growth-colony-stimulating-factor and a long-acting form of filgrastim that stimulates the production of WBCs and stem cells

Click here to read full press release/ article | Ref: Coherus Biosciences | Image: Stocks News Feed

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post